Drug-Induced Subacute Cutaneous Lupus Erythematosus—Filling the Gap in Knowledge

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review

“…The major morphological characteristics of SCLE are annular, non-scarring, papulosquamous or psoriasiform plaques with distribution mainly to the sunlight exposed areas of the body [13] . The autoimmune profile of SCLE may consist of positive Ro/SSA or La/SSB antibody titles while most patients test positive for antinuclear antibodies (ANA) [14] .…”

Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report

“…In the case presented, given the temporal relationship of the patient’s dermatological toxicities to her chemotherapy treatment, we postulate that the taxane docetaxel is the most likely culprit. In the current literature, there have been eight reported cases of SCLE associated with docetaxel, and five reported cases of SCLE associated with paclitaxel chemotherapy [ 1 – 13 ]. Many of the patients in these cases had a background of preceding autoimmune disease with positive anti-SSA/Ro antibodies [ 1 – 5 , 8 , 10 , 11 ].…”

“…In the current literature, there have been eight reported cases of SCLE associated with docetaxel, and five reported cases of SCLE associated with paclitaxel chemotherapy [ 1 – 13 ]. Many of the patients in these cases had a background of preceding autoimmune disease with positive anti-SSA/Ro antibodies [ 1 – 5 , 8 , 10 , 11 ]. It has been suggested that the presence of serum anti-SSA/Ro antibodies may be involved in a mechanism that predisposes patients to a higher risk of developing drug-induced SCLE [ 4 , 14 ].…”

“…Subacute cutaneous lupus erythematosus (SCLE) is a type of cutaneous lupus erythematosus, most commonly characterized by photodistributed, non-scarring, papulosquamous or polycyclic annular plaques. SCLE is often associated with high titers of anti-SSA/Ro antibodies in the serum, and roughly 20% of newly diagnosed cases of SCLE are attributed to a drug or another exacerbating agent [ 1 ]. Development of drug-induced SCLE has been linked to a number of pharmacological agents including thiazide diuretics, calcium channel blockers, angiotensin converting enzyme inhibitors, and taxanes [ 2 , 3 ].…”

Thalidomide-Induced Orofacial Neuropathy

“…Since drug-induced SCLE was described in 1985, over 100 medications have been implicated [3,4]. Terbinafine is one of the most commonly reported agents for inducing SCLE [5].…”